The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...

VIJAYAWADA: Sickle cell anaemia and thalassemia remain major health concerns in the State, particularly among tribal ...

More recently, Bluebird Bio’s Zynteglo (betibeglogene autotemcel), a cell-based gene therapy to treat transfusion-dependent beta-thalassemia (TDT), has been slow to gain traction in the market.

If human genetics were a tech company ... in nonviable human embryos to try to fix the genetic defect that causes beta-thalassemia, a potentially fatal blood disorder. Their attempt failed ...